---
layout: default
title: Bifonazole
parent: 僅模型預測 (L5)
nav_order: 101
evidence_level: L5
indication_count: 0
---

# Bifonazole
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Bifonazole: Antifungal Agent — Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

Bifonazole (DrugBank: DB04794) is an imidazole-class antifungal agent used topically for superficial fungal infections; it currently holds no MHRA marketing authorisation in the United Kingdom.
The TxGNN model did **not generate any repurposing predictions** for this compound in the current analysis run, which may reflect missing upstream data rather than a genuine absence of repurposing potential.
Critical data gaps — including mechanism of action and SmPC safety information — prevent a substantive evaluation at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No UK-registered indications recorded; pharmacological class suggests superficial fungal infections |
| Predicted New Indication | No predictions generated in this run |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — pipeline could not complete |
| UK Market Status | Not marketed in the United Kingdom |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Safety Considerations

No safety data are currently available in this Evidence Pack. Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline returned no repurposing predictions for bifonazole; this is most likely attributable to two blocking data gaps — the absence of mechanism of action (MOA) information and the absence of MHRA SmPC content — rather than a confirmed lack of repurposing signal. Proceeding to any clinical or regulatory assessment without these foundational inputs would be premature.

**To proceed, the following is needed:**

- **Retrieve MOA from DrugBank** — Query the DrugBank API for DB04794 to obtain mechanism of action, pharmacodynamics, and drug categories; this is required before the TxGNN graph embedding can be properly anchored.
- **Obtain MHRA/EMA product information** — Download and parse the SmPC (or EMA EPAR if applicable) to populate warnings, contraindications, and DDI data, which are currently blocking the S1 safety screen.
- **Re-run the TxGNN prediction pipeline** — After the above gaps are resolved, re-run the full KG + DL prediction workflow to confirm whether predictions are genuinely absent or were suppressed by missing node features.
- **Verify UK regulatory status** — Confirm whether bifonazole has ever held an MHRA authorisation (including historic or withdrawn licences) or whether any product containing it is available under a different INN, combination name, or brand name in the UK market.
- **Cross-reference EU/EEA approvals** — Check the EMA product database and EU CTR for any existing indications that could serve as a starting point for repurposing hypothesis generation.

> ⚠️ **Research Disclaimer:** This report is for research reference only and does not constitute medical advice. Any drug repurposing candidate must undergo clinical validation before application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

